rs397508488
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PP3_StrongPP5
The NM_000492.4(CFTR):c.3047T>C(p.Phe1016Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000137 in 1,461,288 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: not found (cov: 31)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
CFTR
NM_000492.4 missense
NM_000492.4 missense
Scores
9
8
2
Clinical Significance
Conservation
PhyloP100: 7.62
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
PM1
?
In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 1 benign, 10 uncertain in NM_000492.4
PM2
?
Very rare variant in population databases, with high coverage;
PP3
?
MetaRNN computational evidence supports a deleterious effect, 0.951
PP5
?
Variant 7-117610577-T-C is Pathogenic according to our data. Variant chr7-117610577-T-C is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 53640.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=3, Uncertain_significance=3, not_provided=1}. Variant chr7-117610577-T-C is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3047T>C | p.Phe1016Ser | missense_variant | 19/27 | ENST00000003084.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.3047T>C | p.Phe1016Ser | missense_variant | 19/27 | 1 | NM_000492.4 | P2 | |
ENST00000456270.1 | n.178-5588A>G | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes ? Cov.: 31
GnomAD3 genomes
?
Cov.:
31
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251134Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135730
GnomAD3 exomes
AF:
AC:
2
AN:
251134
Hom.:
AF XY:
AC XY:
0
AN XY:
135730
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461288Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 726946
GnomAD4 exome
AF:
AC:
2
AN:
1461288
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
726946
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome ? Cov.: 31
GnomAD4 genome
?
Cov.:
31
ExAC
?
AF:
AC:
2
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:3Uncertain:3Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Cystic fibrosis Pathogenic:2Uncertain:2Other:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Dec 27, 2022 | CFTR variant associated with varying clinical consequence. See www.CFTR2.org for phenotype information. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 31, 2023 | The p.F1016S variant (also known as c.3047T>C), located in coding exon 19 of the CFTR gene, results from a T to C substitution at nucleotide position 3047. The phenylalanine at codon 1016 is replaced by serine, an amino acid with highly dissimilar properties. This variant has been detected in conjunction with p.L102R in the CFTR gene in multiple individuals; family studies indicated that these two variants are on the same chromosome (Ambry internal data). This variant was first reported in an individual with cystic fibrosis in conjunction with a frameshift variant (Alper OM et al. Hum. Mutat., 2004 Oct;24:353). This variant has also been detected in an individual with an abnormal newborn screening with elevated sweat chloride levels and pancreatic insufficiency in conjunction with p.L102R and p.F508del (Salinas DB et al. PLoS One, 2016 May;11:e0155624). In CFBE cells, this variant had significantly reduced CFTR function compared to wild type, and the function improved with CFTR modulators (Han ST et al. JCI Insight, 2018 07;3:). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. - |
not provided, no classification provided | literature only | ClinVar Staff, National Center for Biotechnology Information (NCBI) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Oct 24, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Invitae | Aug 20, 2021 | This variant has been observed in individual(s) with clinical features of cystic fibrosis (PMID: 15365999, 27214204; Invitae). This variant is present in population databases (rs397508488, ExAC 0.009%). This sequence change replaces phenylalanine with serine at codon 1016 of the CFTR protein (p.Phe1016Ser). The phenylalanine residue is highly conserved and there is a large physicochemical difference between phenylalanine and serine. ClinVar contains an entry for this variant (Variation ID: 53640). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C55"). Experimental studies have shown that this variant affects CFTR function (PMID: 30046002). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 25, 2024 | Variant summary: CFTR c.3047T>C (p.Phe1016Ser) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 251134 control chromosomes. c.3047T>C has been reported in the literature in at least one individual affected with Cystic Fibrosis (e.g. Alper_2004, Kharazzi_2015).The variant has also been detected in one patient reportedly affected by CF who was genotyped by our laboratory. The variant was found to be in cis with another variant of uncertain significance, c.305T>C (p.Leu102Arg), in at least two individuals (internal testing). At least one functional study reports this variant to result in decreased CFTR activity (Han_2018). The following publications have been ascertained in the context of this evaluation (PMID: 15365999, 30046002, 26574590, 25735457, 27214204, 18556774, 15300780). ClinVar contains an entry for this variant (Variation ID: 53640). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
Cadd
Pathogenic
Dann
Uncertain
DEOGEN2
Uncertain
D;.;.;D;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;.;.;.
MutationTaster
Benign
D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;.;.;N;.
REVEL
Pathogenic
Sift
Uncertain
D;.;.;D;.
Sift4G
Pathogenic
D;.;.;D;.
Polyphen
P;.;.;.;.
Vest4
MutPred
Loss of catalytic residue at F1016 (P = 0.0557);.;.;.;.;
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at